Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
Launched by GILEAD SCIENCES · Feb 21, 2012
Trial Information
Current as of April 26, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Individuals in the primary Phase 3 study (Study GS-US-312-0116) who are compliant
- • Tolerating primary study therapy
- • Note: Other protocol defined Inclusion/Exclusion criteria may apply.
About Gilead Sciences
Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to address unmet medical needs. With a strong emphasis on antiviral therapies, particularly for HIV, hepatitis B, hepatitis C, and influenza, Gilead leverages advanced research and development capabilities to drive breakthroughs in treatment and care. The company is committed to improving patient outcomes through rigorous clinical trials, fostering collaborations with healthcare professionals, and engaging in partnerships to enhance global health. Gilead's dedication to scientific excellence and patient-centric approaches positions it at the forefront of the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
New York, New York, United States
Milwaukee, Wisconsin, United States
Rouen, , France
Roanoke, Virginia, United States
Hackensack, New Jersey, United States
New York, New York, United States
Bournemouth, , United Kingdom
Denver, Colorado, United States
Greenville, South Carolina, United States
Pierre Benite, , France
Nashville, Tennessee, United States
New Hyde Park, New York, United States
Fort Worth, Texas, United States
Houston, Texas, United States
London, , United Kingdom
Washington, District Of Columbia, United States
Huntsville, Alabama, United States
Fort Myers, Florida, United States
Oxnard, California, United States
Southampton, , United Kingdom
New York, New York, United States
Liverpool, , United Kingdom
Yakima, Washington, United States
Fairfax, Virginia, United States
Springfield, Oregon, United States
Stanford, California, United States
New York, New York, United States
Denver, Colorado, United States
Tualatin, Oregon, United States
Cambridge, , United Kingdom
Tucson, Arizona, United States
San Antonio, Texas, United States
Boynton Beach, Florida, United States
Leeds, , United Kingdom
Harrow, , United Kingdom
Köln, , Germany
Santa Monica, California, United States
Saint Petersburg, Florida, United States
Dorchester, , United Kingdom
La Jolla, California, United States
Seattle, Washington, United States
Erlangen, , Germany
Milano, , Italy
Torino, , Italy
Orpington, , United Kingdom
Patients applied
Trial Officials
Gilead Study Director
Study Director
Gilead Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials